MedTrace Logo

Molecular and Functional Imaging in Monogenic PD.

NCT05518617 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 45

Last updated 2025-10-07

No results posted yet for this study

Summary

In this study, the investigators aim to find a biomarker of Parkinson's disease. This is done using imaging scans called Positron Emission tomography (PET), Single Photon Emission Computed Tomography (SPECT), and Magnetic Resonance Imaging (MRI). The findings will provide a deeper understanding of the brain changes in Parkinson's disease. More importantly, this study will help with the discovery and development of new medications aiming to delay progression of PD symptoms.

Conditions

Interventions

OTHER

Positron Emission Tomography (PET) scan using DASB tracer

DASB is a highly selective PET radioligand for serotonin transporter and is a reliable tool to investigate serotonin terminals and neurons. The included Magnetic Resonance Imaging (MRI) sequences serve to provide additional information plus complement PET data. To quantify dopaminergic pathology with \[123I\]FP-CIT SPECT,

Sponsors & Collaborators

  • University of Exeter

    lead OTHER

Principal Investigators

  • Marios Politits, Professor · The University of Exeter

Eligibility

Min Age
25 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-01
Primary Completion
2026-06-30
Completion
2026-06-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05518617 on ClinicalTrials.gov